NCT03839459View on ClinicalTrials.gov

Denosumab for Smoldering Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

September 16, 2022

Study Completion Date

January 30, 2025

Conditions
Smoldering Multiple Myeloma
Interventions
DRUG

Denosumab

120mg of Denosumab will be administered subcutaneously once every 4 weeks

Trial Locations (1)

14642

University of Rochester, Rochester

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of Rochester

OTHER

NCT03839459 - Denosumab for Smoldering Multiple Myeloma | Biotech Hunter | Biotech Hunter